Repligen Corporation (NASDAQ:RGEN, “Repligen”), a life sciences company focused on bioprocessing technology leadership, has acquired privately held Tantti Laboratory Inc. (“Tantti”) of Taoyuan City, Taiwan. Tantti has developed a unique portfolio of macroporous chromatography beads to optimize the purification of new modalities including viral vectors, viruses, nucleic acids and other large molecule biologics.

Tantti is a biomaterials engineering company developing bioprocessing solutions for use in the development and production of innovative biologic products and advanced cell and gene therapies. Its key product technology platforms include DuloCore, a new class of convective chromatography bead resin designed for the purification of large biomolecules (e.g., viral vectors, nucleic acids, and viruses). Founded in 2014, Tantti’s technologies have received patent approval around the world, including in the United States, Europe, Japan, Taiwan and China.

Repligen is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The Company primarily serves biopharmaceutical drug developers and CDMOs worldwide. Focus areas include Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Repligen’s corporate headquarters are in Waltham, Massachusetts, and the majority of the Company’s manufacturing sites are in the U.S.

EC M&A acted as exclusive financial advisor to Repligen on this transaction.